Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27707919 | 0.97 | LOXL2 (0.56) | LOXL2CYP2A6CA2CA12CA3 | |
| Hydrogen Sulfide SCHEMBL27473257 | 0.97 | LOXL2 (0.56) | LOXL2CYP2A6CA2CA12CA3 | |
| SCHEMBL31591073 | 0.93 | SAE1 (0.56) | LOXL2CYP2A6CA2CA12CA3 | |
| SCHEMBL12807987 | 0.93 | MMP3 (0.58) | LOXL2CYP2A6CA2CA12CA3 | |
| SCHEMBL3236728 | 0.93 | MMP3 (0.58) | LOXL2CYP2A6CA2CA12CA3 | |
| Phosphoric Acid SCHEMBL28852152 | 0.89 | LOXL2 (0.48) | LOXL2CYP2A6CA2CA12CA3 | |
| Ammonia Solution, Strong SCHEMBL3944504 | 0.89 | LOXL2 (0.48) | LOXL2CYP2A6CA2CA12CA3 | |
| SCHEMBL3233441 | 0.87 | LTA4H (0.59) | LOXL2CYP2A6IDO1CYP11B1CYP11B2 | |
| SCHEMBL17253336 | 0.87 | CYP1B1 (0.47) | LOXL2CYP2A6CA2CA12CA3 | |
| SCHEMBL3178059 | 0.87 | MAOB (0.59) | LOXL2CYP2A6CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968367-A | Novel heterocyclylphenylmethylamine derivatives, process for their preparation and their use for preventing, alleviating or treating multiple sclerosis | 韩国科学技术研究院 | 2025-05-09 | — | — | CN | claimed |
| WO-2025053791-A1 | ONE-POT GRAFTING OF POLYMERS FROM ALCOHOLS AND BIOMASSES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| CN-116440926-B | Modified ZnIn2S4/BiVO4Heterojunction between benzyl alcohol and CO2Application in photocatalytic carboxylation | 重庆工商大学 | 2024-07-02 | — | — | CN | claimed |
| CN-112204024-B | ERK inhibitor and application thereof | 贝达药业股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2024029638-A1 | NOVEL HETEROCYCLYL-PHENYL-METHYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF FOR PREVENTION, ALLEVIATION, OR TREATMENT OF MULTIPLE SCLEROSIS | 한국과학기술연구원 | 2024-02-08 | — | — | WO | claimed |
| CN-116555080-A | Preparation method of hybrid ester compound containing oxazole ring | 上海交通大学医学院附属仁济医院 | 2023-08-08 | — | — | CN | claimed |
| CN-116440926-A | Modified ZnIn 2 S 4 /BiVO 4 Heterojunction between benzyl alcohol and CO 2 Application in photocatalytic carboxylation | 重庆工商大学 | 2023-07-18 | — | — | CN | claimed |
| CN-113024530-B | Isatin-1, 2, 4-oxadiazole compound and preparation method and application thereof | 合肥工业大学 | 2023-07-18 | — | — | CN | claimed |
| CN-116102554-A | Naphthalimide bicyclic compound, preparation method and application thereof | 首都师范大学 | 2023-05-12 | — | — | CN | claimed |
| CN-115925675-A | Psamaplin A derivative and preparation method and application thereof | 中国海洋大学 | 2023-04-07 | — | — | CN | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| US-6187945-B1 | TRANSFORMING AN AMINOMETHYL GROUP OF A CYANOBENZYLAMINE COMPOUND INTO A HYDROXYMETHYL GROUP, A HALOMETHYL GROUP, OR AN ACYLOXYMETHYL GROUP BY DIAZOTIZATION AND HYDROXYLATION, HALOGENATION OR ACYLATION | SHOWA DENKO K.K. (JP) | 2001-02-13 | — | — | US | claimed |
| EP-1004574-A1 | Process for producing cyanobenzyl compounds | Showa Denko Kabushiki Kaisha (JP) | 2000-05-31 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | claimed |
| EP-0237522-B1 | PHARMACEUTICALLY ACTIVE DERIVATIVES OF TRYPTOPHAN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1993-02-24 | — | — | EP | claimed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | claimed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | LOXL2 2440/4885CYP2A6 2117/4885CA2 4562/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | LOXL2 2705/4885CYP2A6 3085/4885CA2 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.